| Product vision |
- Product targeting prevention of relapse for P. vivax
- Product for transmission reduction
|
| Dosing |
- 2.5 mg and 5 mg Primaquine dispersible tablets, 14-day course in all transmission settings to prevent relapse, treat P. vivax or P. ovale malaria in children and adults
- To reduce the transmissibility of treated P. falciparum infections: In low-transmission areas, give a single dose of 0.25 mg/kg primaquine with ACT to patients with P. falciparum malaria (except pregnant women, infants aged < 6 months and women breastfeeding infants aged < 6 months)
|
| Efficacy |
- WHO guidelines recommend primaquine to prevent relapse, treat P. vivax or P. ovale malaria in children and adults (except pregnant women, infants aged < 6 months, women breastfeeding infants aged < 6 months, women breastfeeding older infants unless they are known not to be G6PD deficient, and people with G6PD deficiency)
|
| Key features |
- Would be first child friendly dispersible formulation
|
| Challenges |
- Limited use in low transmission settings
|
| Status |
- Prototype developed and tech transfer undertaken
- Bioequivalence study protocol WHO Ethics Review Committee (ECR) approved
|
| Next milestone |
- Bioequivalence study start
|
| MMV Project Director |
|
